Phase III trial of personalized mRNA melanoma vaccine shows positive efficacy in high-risk patients

A phase III clinical trial involving 1,137 high-risk melanoma patients demonstrated positive outcomes using a personalized mRNA vaccine in combination with immunotherapy. While the results are encouraging for oncology, the full dataset remains pending, leaving the precise magnitude of clinical benefit and long-term durability uncertain.